SIGY
SIGYN THERAPEUTICS INC
Latest price
As of — · Market data by Massive
Market cap
—
Volume
0
Previous close
$0.0304
Day range
$0.0000 – $0.0000
Listed
—
Coverage
8 articles
Price performance
Recent trading
Newsroom
Latest SIGY coverage
Sigyn Therapeutics Releases Letter to Shareholders
[ad_1] SAN DIEGO, CA – (NewMediaWire) – January 04, 2024 – Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced the release of a shareholder letter authored by Chairman and Chief Executive Officer, Jim Joyce. Dear Fellow Shareholder, As a small organization operat
Sigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial Officer
[ad_1] SAN DIEGO, CA – (NewMediaWire) – December 12, 2023 – Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced the appointment of Jerry DeCiccio, CPA, MBA, as Chief Financial Officer. Mr. DeCiccio brings more than 40 years of financial industry experience to the
Presenting on the Emerging Growth Conference on August 9 & 10 Register Now
EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 60th Emerging Growth Conference on August 9, 10, 2023.
Sigyn Therapeutics Discloses "DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES" Patent Submission and Related ImmunePrepTM Trademark Application
[ad_1] SAN DIEGO, CA – (NewMediaWire) – May 17, 2023 – Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, disclosed today that it has submitted a provisional patent application entitled: “DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES” to the United States Patent
Sigyn Therapeutics Appoints Accomplished Financial Executive, Jeremy Ferrell, as Chief Financial Officer
[ad_1] SAN DIEGO, CA – (NewMediaWire) – March 02, 2022 – via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets:“SIGY”), a medical technology company focused on the treatment of pathogen-associated conditions that induce sepsis, today announced the appointment of Jeremy Ferrell, CPA, MBA as Chief Financial Officer (“CFO”), effective March
Sigyn Therapeutics Announces Successful Completion of Animal Pilot Study
[ad_1] San Diego, CA – (NewMediaWire) – July 29, 2021 – Sigyn Therapeutics, Inc. (OTC Markets: SIGY), a medical technology company focused on the treatment of life-threatening inflammatory conditions, today announced the completion of a pilot animal study that validated the feasibility of a clinical protocol that resulted in the safe admini
Sigyn Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
[ad_1] San Diego – (NewMediaWire) – March 8, 2021 – Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on the treatment of life-threatening inflammatory conditions precipitated by Cytokine Storm Syndrome (the Cytokine Storm), today announced that Jim Joyce, its Chairman and Chief Executive
Sigyn Therapeutics Announces Completion of Merger with Reign Resources
[ad_1] Sigyn is Focused on the Treatment of Sepsis and Other Life-Threatening Inflammatory Conditions That are Not Addressed with Approved Drug Therapies Trading to Commence Tomorrow Under the Ticker Symbol “SIGY” San Diego, California – (NewMediaWire) – October 19, 2020 – Sigyn Therapeutics, Inc., a medical technology c